- Report
- May 2026
- 148 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 130 Pages
Global
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 400 Pages
Global
From €4501EUR$4,949USD£3,856GBP
- Report
- February 2026
- 95 Pages
Global
From €3500EUR$4,123USD£3,104GBP
- Report
- December 2025
- 135 Pages
Global
From €4411EUR$4,850USD£3,779GBP
- Report
- October 2025
- 140 Pages
Global
From €4411EUR$4,850USD£3,779GBP
- Report
- October 2025
- 150 Pages
Global
From €4411EUR$4,850USD£3,779GBP
- Report
- October 2025
- 96 Pages
Global
From €4411EUR$4,850USD£3,779GBP
- Report
- August 2025
- 100 Pages
Middle East
From €4502EUR$4,950USD£3,857GBP
- Report
- May 2026
- 102 Pages
Middle East
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 85 Pages
Africa
From €2592EUR$2,850USD£2,221GBP
- Report
- October 2025
- 87 Pages
Middle East
From €4411EUR$4,850USD£3,779GBP
- Report
- June 2023
- 289 Pages
Global
From €4772EUR$5,431USD£3,950GBP
- Report
- January 2025
- 456 Pages
Global
From €4502EUR$4,950USD£3,857GBP
- Report
- December 2024
- 313 Pages
Global
From €4502EUR$4,950USD£3,857GBP
- Report
- July 2026
Global
From €450EUR$530USD£399GBP
- Report
- July 2026
Global
From €300EUR$353USD£266GBP
- Report
- December 2024
- 581 Pages
Global
From €4502EUR$4,950USD£3,857GBP
- Report
- August 2023
- 270 Pages
Global
From €2228EUR$2,450USD£1,909GBP
- Report
- June 2023
- 186 Pages
Global
From €4229EUR$4,650USD£3,623GBP

Prostate cancer is a type of cancer that affects the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is the most common cancer in men in the United States, and the second most common cause of cancer death in men. Prostate cancer is typically treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments.
The prostate cancer market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to benefit from the introduction of novel therapies, such as immunotherapies and targeted therapies, which are expected to improve the prognosis of patients. Additionally, the increasing focus on early diagnosis and the development of new diagnostic tools are expected to drive the market growth.
Some of the key players in the prostate cancer market include AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more